×

Restorgenex Corporation (RESX) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10

NEW YORK, June 4, 2015 (GLOBE NEWSWIRE) -- Restorgenex Corporation (OTCMKTS:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.

Restorgenex Corporation's Presenter: Stephen M. Simes, CEO

Time: 2:30 pm to 2:50 pm (ET)

Equities.com designed this full-day event dedicated to creating unparalleled discovery and exclusive networking sessions. For more details on the conference, please visit http://www.equitiesevents.com.

Registration for the conference is still available but space is limited. We encourage you to register by clicking this link (http://bit.ly/1Q7aMRx) as soon as possible to ensure your participation. Presenters and attendees can schedule private one-on-one meetings to maximize their networking opportunities.

Participation in this exclusive conference is for institutional investors interested in small-cap and pre-IPO opportunities. In attendance will be: Hedge Funds, Family Offices, Portfolio Managers, Investment Banks and Venture Capitalists.

To learn more about how you can participate and to stay up-to-date on all conference-related news, please visit www.equitiesevents.com.

To register for the conference, please visit: http://bit.ly/1Q7aMRx

About RestorGenex Corporation

RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: www.restorgenex.com.

About Equities.com, Inc.

Equities.com is an online financial news organization and social community for self-directed investors, public and private companies, market experts, and professional service providers across the global capital markets. The Equities.com Issuer Dashboard is an ideal SaaS platform to effectively manage corporate communication and investor awareness campaigns, engage with market intermediaries and financial advisors, and research industry peers. Registered members can leverage our market-leading commentary and content curation, as well as our proprietary research tools, such as our robust do-it-yourself Equities Valuation Analysis (E.V.A.) research reports. Go to http://www.equities.com/community/register to become a member.

CONTACT: Danielle Blackwell Conference and Event Director Office: 310-822-5500 ext 135 danielle@equities.comSource:Restorgenex Corporation